<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03134911</url>
  </required_header>
  <id_info>
    <org_study_id>1160-0280</org_study_id>
    <nct_id>NCT03134911</nct_id>
  </id_info>
  <brief_title>Health-related Quality of Life in Patients on Anticoagulants</brief_title>
  <acronym>RE-QUOL</acronym>
  <official_title>Non-Interventional, Cross-sectional Study to Describe Health-related Quality of Life Among Controlled and Uncontrolled Patients With Nonvalvular Atrial Fibrillation on Anticoagulants. RE-QUOL Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study has been designed to describe the health-related quality of life in
      patients with non valvular atrial fibrillation who have been prescribed a specific
      anticoagulant treatment for their non valvular atrial fibrilation at least 6 months prior to
      study initiation. It will be conducted in Departments of Internal Medicine from approximately
      50 centers in Spain. It consists of an only visit that will coincide with one of those
      performed by the patients as part of routine follow-up of their disease. 500 patients seen in
      internal medicine are planned to be included in the study
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 24, 2017</start_date>
  <completion_date type="Actual">January 31, 2018</completion_date>
  <primary_completion_date type="Actual">January 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Health Related Quality of Life (QoL) (HRQoL) Scores in the Spanish Adaptation of the Sawicki Questionnaire</measure>
    <time_frame>The study consisted of a single visit between April 2017 and January 2018</time_frame>
    <description>Sawicki questionnaire includes 32 items grouped in 5 dimensions: 1) general treatment satisfaction, 2) self-efficacy, 3) strained social network, 4) daily hassles and 5) distress. Patients estimated the impact of each item on their self-perceived treatment-related QoL on a scale of 1 (total disagreement) to 6 (total agreement). Response options for each question were: 1=not at all, 2=very little, 3=a little, 4=somewhat, 5=a lot, 6=very much. High scores in general treatment satisfaction and self-efficacy dimensions indicate high perceived HRQoL. Low scores in the strained social network, daily hassles and distress dimensions indicate high perceived HRQoL. The summary score for each dimension was calculated by dividing the total score of the sum of the items that comprise each dimension into the number of items included in that dimension. For the general treatment satisfaction dimension, the scores of individual questions have to be inverted first to calculate the dimension score.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Demographic Data of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients</measure>
    <time_frame>The study consisted of a single visit between April 2017 and January 2018</time_frame>
    <description>Age group, work status and life status of uncontrolled non-valvular atrial fibrillation (NVAF) patients is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Height of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients</measure>
    <time_frame>The study consisted of a single visit between April 2017 and January 2018</time_frame>
    <description>Height of uncontrolled non-valvular atrial fibrillation (NVAF) patients is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients</measure>
    <time_frame>The study consisted of a single visit between April 2017 and January 2018</time_frame>
    <description>Weight of uncontrolled non-valvular atrial fibrillation (NVAF) patients is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index (BMI) of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients</measure>
    <time_frame>The study consisted of a single visit between April 2017 and January 2018</time_frame>
    <description>BMI of uncontrolled non-valvular atrial fibrillation (NVAF) patients is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney Function (Creatinine Clearance) of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients</measure>
    <time_frame>The study consisted of a single visit between April 2017 and January 2018</time_frame>
    <description>Kidney function of uncontrolled non-valvular atrial fibrillation (NVAF) patients measured by creatinine clearance is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>History of Non-valvular Atrial Fibrillation (NVAF) - Time Since Diagnosis</measure>
    <time_frame>The study consisted of a single visit between April 2017 and January 2018</time_frame>
    <description>Analysis of data regarding the specific NVAF profile of uncontrolled patients indicated that the average (± SD) time since diagnosis (calculated as the time from the date of diagnosis to the date of the baseline visit).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>History of Non-valvular Atrial Fibrillation (NVAF) - Age at Diagnosis</measure>
    <time_frame>The study consisted of a single visit between April 2017 and January 2018</time_frame>
    <description>Age at diagnosis of uncontrolled non-valvular atrial fibrillation (NVAF) patients is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Ejection Fraction (LVEF) of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients</measure>
    <time_frame>The study consisted of a single visit between April 2017 and January 2018</time_frame>
    <description>Left ventricular ejection fraction (LVEF) of uncontrolled non-valvular atrial fibrillation (NVAF) patients is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Left Ventricular Ejection Fraction (LVEF) Depression of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients</measure>
    <time_frame>The study consisted of a single visit between April 2017 and January 2018</time_frame>
    <description>Percentage of patients with left ventricular ejection fraction (LVEF) depression (% of LVEF depression) of uncontrolled non-valvular atrial fibrillation (NVAF) patients is presented qualitatively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CHA2DS2-VASc Score of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients</measure>
    <time_frame>The study consisted of a single visit between April 2017 and January 2018</time_frame>
    <description>CHA2DS2-VASc stroke risk score is calculated based on the following conditions: Congestive heart failure, Hypertension, Age (≥ 75), Diabetes Mellitus, Stroke/ Transient Ischaemic Attack (TIA), Vascular disease, Age 65-74, Sex category. CHA2DS2-VASc stroke risk score may range from 0 to 9 with 0 being the best outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HAS-BLED Score of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients</measure>
    <time_frame>The study consisted of a single visit between April 2017 and January 2018</time_frame>
    <description>HAS-BLED bleeding risk score is calculated based on the following conditions: Hypertension, Abnormal renal and liver function, Stroke, Bleeding history or predisposition, Labile International Normalized Ratio (INR), Elderly (&gt;65 years), Drugs and Alcohol. HAS-BLED bleeding risk score may range from 0 to 9 with 0 being the best outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients With History of Thromboembolic Events by Categories</measure>
    <time_frame>The study consisted of a single visit between April 2017 and January 2018</time_frame>
    <description>Percentage of uncontrolled non-valvular atrial fibrillation (NVAF) patients with history of thromboembolic events by categories are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients With History of Haemorrhagic Events by Categories</measure>
    <time_frame>The study consisted of a single visit between April 2017 and January 2018</time_frame>
    <description>Percentage of uncontrolled non-valvular atrial fibrillation (NVAF) patients with history of haemorrhagic events by categories are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Visits to the Physician of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients</measure>
    <time_frame>The study consisted of a single visit between April 2017 and January 2018</time_frame>
    <description>Number of visits to the internal medicine specialist per year of uncontrolled non-valvular atrial fibrillation (NVAF) patients is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapeutic Time in Range (TTR%) of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients</measure>
    <time_frame>The study consisted of a single visit between April 2017 and January 2018</time_frame>
    <description>Therapeutic time in range (TTR%) of uncontrolled non-valvular atrial fibrillation (NVAF) patients determined by the Rosendaal method (poor control &lt; 65%) or by the direct method (poor control &lt; 60%).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Since Treatment Initiation of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients</measure>
    <time_frame>The study consisted of a single visit between April 2017 and January 2018</time_frame>
    <description>Time since treatment initiation of uncontrolled non-valvular atrial fibrillation (NVAF) patients was calculated as the time from the start date of treatment to the date of the baseline visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients Received Type of VKA Treatment</measure>
    <time_frame>The study consisted of a single visit between April 2017 and January 2018</time_frame>
    <description>Percentage of uncontrolled non-valvular atrial fibrillation (NVAF) patients received type VKA treatment is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients With Concomitant Diseases</measure>
    <time_frame>The study consisted of a single visit between April 2017 and January 2018</time_frame>
    <description>The percentage of uncontrolled non-valvular atrial fibrillation (NVAF) patients with at least one other concomitant diseases recorded in the medical history.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients With Active Concomitant Diseases on Visit Day</measure>
    <time_frame>The study consisted of a single visit between April 2017 and January 2018</time_frame>
    <description>The percentage of uncontrolled non-valvular atrial fibrillation (NVAF) patients with active concomitant diseases on visit day. The percentage was calculated on total patients who presented each of the diseases.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients With Concomitant Treatment</measure>
    <time_frame>The study consisted of a single visit between April 2017 and January 2018</time_frame>
    <description>The percentage of uncontrolled non-valvular atrial fibrillation (NVAF) patients with concomitant treatment is presented.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">535</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>anticoagulation controlled patients</arm_group_label>
    <description>Treated with DOAC or VKA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>anticoagulation non controlled patients</arm_group_label>
    <description>Treated with VKA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DOAC or VKA</intervention_name>
    <description>6 months - 2 years</description>
    <arm_group_label>anticoagulation controlled patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VKA</intervention_name>
    <description>6 months - 2 years</description>
    <arm_group_label>anticoagulation non controlled patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed of non valvular atrial fibrillation and prescribed DOACs or VKA, who are
        seen in internal medicine from hospitals of 3 Autonomous Communities in Spain (Madrid,
        Comunidad Valenciana, Andalucía)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient is willing and provides written informed consent to participate in this
             study.

          -  The patient is at least 18 years of age

          -  The patient has a diagnosis of non-valvular atrial fibrillation

          -  The patient is on the same anticoagulant therapy (VKA or DOAC) during at least 6
             months and maximum 2 years.

          -  If treated with VKA, availability of % Time in Therapeutic Range (TTR) in past
             analytical records or enough amount of International Normalized Ratio (INR) measures
             to calculate it.

        Exclusion Criteria:

          -  Current participation in any clinical trial of a drug or device

          -  Contraindication to the use of DOAC or VKA as described in the Summary of Product
             Characteristics (SmPC).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mireia Canals, +34607550925</last_name>
    <role>Study Chair</role>
    <affiliation>mireia.canals@boehringer-ingelheim.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario Príncipe de Asturias</name>
      <address>
        <city>Alcalá De Henares (Madrid)</city>
        <zip>28805</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HospitalUniversitario Príncipe de Asturias</name>
      <address>
        <city>Alcalá De Henares (Madrid)</city>
        <zip>28805</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospita Universitario Fundación Alcorcón</name>
      <address>
        <city>Alcorcón (Madrid)</city>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Público Virgen de los Lirios</name>
      <address>
        <city>Alcoy (Alicante)</city>
        <zip>03804</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario San Juan de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03550</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Torrecárdenas</name>
      <address>
        <city>Almería</city>
        <zip>04009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Monteprincipe</name>
      <address>
        <city>Boadilla Del Monte (Madrid)</city>
        <zip>28660</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Juan de Dios</name>
      <address>
        <city>Bormujos (Sevilla)</city>
        <zip>41930</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Castellón</name>
      <address>
        <city>Castellón De La Plana (Castellón)</city>
        <zip>12004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Elche</name>
      <address>
        <city>Elche (Alicante)</city>
        <zip>03203</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Fuenlabrada</name>
      <address>
        <city>Fuenlabrada (Madrid)</city>
        <zip>28942</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Comarcal Francesc de Borja</name>
      <address>
        <city>Gandía (València)</city>
        <zip>46702</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Arnau de Vilanova</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital De Llíria (depende del Arnau de Vilanova)</name>
      <address>
        <city>Llíria (Valencia)</city>
        <zip>46160</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Doce de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro</name>
      <address>
        <city>Majadahonda (Madrid)</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Costa del Sol</name>
      <address>
        <city>Marbella (Málaga)</city>
        <zip>29603</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Especialidades Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Regional de Málaga (Carlos Haya)</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Rey Juan Carlos</name>
      <address>
        <city>Móstoles (Madrid)</city>
        <zip>28933</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Móstoles</name>
      <address>
        <city>Móstoles (Madrid)</city>
        <zip>28935</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vega Baja</name>
      <address>
        <city>Orihuela (Alicante)</city>
        <zip>03314</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Camino</name>
      <address>
        <city>Pamplona (Navarra)</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Requena</name>
      <address>
        <city>Requena (Valencia)</city>
        <zip>46340</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Sagunto</name>
      <address>
        <city>Sagunto (Valencia)</city>
        <zip>46520</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Infanta Sofia</name>
      <address>
        <city>San Sebastián De Los Reyes (Madrid)</city>
        <zip>28703</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Torrevieja</name>
      <address>
        <city>Torrrevieja (Alicante)</city>
        <zip>03186</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitariio de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consorcio Hospital General Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de La Plana</name>
      <address>
        <city>Villarreal (Castellón)</city>
        <zip>12540</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Lluis Alcanyis</name>
      <address>
        <city>Xàtiva (Valencia)</city>
        <zip>46800</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
    <description>Related Info</description>
  </link>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>March 1, 2017</study_first_submitted>
  <study_first_submitted_qc>April 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2017</study_first_posted>
  <results_first_submitted>January 21, 2019</results_first_submitted>
  <results_first_submitted_qc>January 21, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 18, 2019</results_first_posted>
  <last_update_submitted>January 21, 2019</last_update_submitted>
  <last_update_submitted_qc>January 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 5, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/11/NCT03134911/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 11, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/11/NCT03134911/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was an observational, multicentre and cross-sectional study conducted in Departments of Internal Medicine from 47 sites in Spain. The patient received the same anticoagulant treatment for at least 6 months and no more than 2 years.</recruitment_details>
      <pre_assignment_details>Data were obtained from a single visit that coincided with one of those performed by the patients as part of routine follow-up of their disease, without interfering with usual clinical practice of the investigator. 535 patients were enrolled and 34 excluded from analysis due to being screening failure and not meeting inclusion/ exclusion criteria.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Total Patients With Non-valvular Atrial Fibrillation</title>
          <description>Patients with non-valvular atrial fibrillation (NVAF) receiving conventional vitamin K antagonist (VKA) treatment with uncontrolled anticoagulation status and VKA or direct oral anticoagulant (DOAC) treatment with controlled anticoagulation status were included. For both the groups treatment were given for at least 6 months and up to 2 years.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="535"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="501"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Screen failure</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not meeting inclusion/exclusion criteria</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All patients with non-valvular atrial fibrillation (NVAF), who received conventional vitamin K antagonist (VKA) with uncontrolled anticoagulation status and those with controlled anticoagulation status receiving VKA or direct oral anticoagulant (DOAC) treatment at least 6 months and up to 2 years were included.</population>
      <group_list>
        <group group_id="B1">
          <title>Uncontrolled Group</title>
          <description>Patients with non-valvular atrial fibrillation (NVAF) receiving conventional vitamin K antagonist (VKA) treatment for at least 6 months and up to 2 years with uncontrolled anticoagulation status were included in this group.</description>
        </group>
        <group group_id="B2">
          <title>Controlled Group</title>
          <description>Patients with non-valvular atrial fibrillation (NVAF), who received conventional vitamin K antagonist (VKA) or direct oral anticoagulant (DOAC) treatment for at least 6 months and up to 2 years with controlled anticoagulation status, were included in this group.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="171"/>
            <count group_id="B2" value="330"/>
            <count group_id="B3" value="501"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="171"/>
                    <count group_id="B2" value="330"/>
                    <count group_id="B3" value="501"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80.4" spread="8.7"/>
                    <measurement group_id="B2" value="79.3" spread="8.8"/>
                    <measurement group_id="B3" value="79.7" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="171"/>
                    <count group_id="B2" value="330"/>
                    <count group_id="B3" value="501"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="152"/>
                    <measurement group_id="B3" value="247"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="178"/>
                    <measurement group_id="B3" value="254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <population>Ethnicity was not reported for this trial.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="171"/>
                    <count group_id="B2" value="330"/>
                    <count group_id="B3" value="501"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="171"/>
                    <measurement group_id="B2" value="330"/>
                    <measurement group_id="B3" value="501"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Health Related Quality of Life (QoL) (HRQoL) Scores in the Spanish Adaptation of the Sawicki Questionnaire</title>
        <description>Sawicki questionnaire includes 32 items grouped in 5 dimensions: 1) general treatment satisfaction, 2) self-efficacy, 3) strained social network, 4) daily hassles and 5) distress. Patients estimated the impact of each item on their self-perceived treatment-related QoL on a scale of 1 (total disagreement) to 6 (total agreement). Response options for each question were: 1=not at all, 2=very little, 3=a little, 4=somewhat, 5=a lot, 6=very much. High scores in general treatment satisfaction and self-efficacy dimensions indicate high perceived HRQoL. Low scores in the strained social network, daily hassles and distress dimensions indicate high perceived HRQoL. The summary score for each dimension was calculated by dividing the total score of the sum of the items that comprise each dimension into the number of items included in that dimension. For the general treatment satisfaction dimension, the scores of individual questions have to be inverted first to calculate the dimension score.</description>
        <time_frame>The study consisted of a single visit between April 2017 and January 2018</time_frame>
        <population>All patients with non-valvular atrial fibrillation (NVAF), who received conventional vitamin K antagonist (VKA) with uncontrolled anticoagulation status and those with controlled anticoagulation status receiving VKA or direct oral anticoagulant (DOAC) treatment at least 6 months and up to 2 years were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Controlled Group</title>
            <description>Patients with non-valvular atrial fibrillation (NVAF), who received conventional vitamin K antagonist (VKA) or direct oral anticoagulant (DOAC) treatment for at least 6 months and up to 2 years with controlled anticoagulation status, were included in this group.</description>
          </group>
          <group group_id="O2">
            <title>Uncontrolled Group</title>
            <description>Patients with non-valvular atrial fibrillation (NVAF) receiving conventional vitamin K antagonist (VKA) treatment for at least 6 months and up to 2 years with uncontrolled anticoagulation status were included in this group.</description>
          </group>
        </group_list>
        <measure>
          <title>Health Related Quality of Life (QoL) (HRQoL) Scores in the Spanish Adaptation of the Sawicki Questionnaire</title>
          <description>Sawicki questionnaire includes 32 items grouped in 5 dimensions: 1) general treatment satisfaction, 2) self-efficacy, 3) strained social network, 4) daily hassles and 5) distress. Patients estimated the impact of each item on their self-perceived treatment-related QoL on a scale of 1 (total disagreement) to 6 (total agreement). Response options for each question were: 1=not at all, 2=very little, 3=a little, 4=somewhat, 5=a lot, 6=very much. High scores in general treatment satisfaction and self-efficacy dimensions indicate high perceived HRQoL. Low scores in the strained social network, daily hassles and distress dimensions indicate high perceived HRQoL. The summary score for each dimension was calculated by dividing the total score of the sum of the items that comprise each dimension into the number of items included in that dimension. For the general treatment satisfaction dimension, the scores of individual questions have to be inverted first to calculate the dimension score.</description>
          <population>All patients with non-valvular atrial fibrillation (NVAF), who received conventional vitamin K antagonist (VKA) with uncontrolled anticoagulation status and those with controlled anticoagulation status receiving VKA or direct oral anticoagulant (DOAC) treatment at least 6 months and up to 2 years were included.</population>
          <units>Unit on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="330"/>
                <count group_id="O2" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment satisfaction</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="321"/>
                    <count group_id="O2" value="166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="1.0"/>
                    <measurement group_id="O2" value="3.6" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Self-efficacy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="321"/>
                    <count group_id="O2" value="166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="1.0"/>
                    <measurement group_id="O2" value="3.6" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Distress</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="319"/>
                    <count group_id="O2" value="166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="0.9"/>
                    <measurement group_id="O2" value="3.9" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Daily hassles</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="313"/>
                    <count group_id="O2" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="0.8"/>
                    <measurement group_id="O2" value="3.0" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strained social network</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="317"/>
                    <count group_id="O2" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="0.9"/>
                    <measurement group_id="O2" value="2.6" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Demographic Data of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients</title>
        <description>Age group, work status and life status of uncontrolled non-valvular atrial fibrillation (NVAF) patients is presented.</description>
        <time_frame>The study consisted of a single visit between April 2017 and January 2018</time_frame>
        <population>All patients with non-valvular atrial fibrillation (NVAF), who received conventional vitamin K antagonist (VKA) treatment at least 6 months and up to 2 years with uncontrolled anticoagulation status were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Uncontrolled Group</title>
            <description>Patients with non-valvular atrial fibrillation (NVAF) receiving conventional vitamin K antagonist (VKA) treatment for at least 6 months and up to 2 years with uncontrolled anticoagulation status were included in this group.</description>
          </group>
        </group_list>
        <measure>
          <title>Demographic Data of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients</title>
          <description>Age group, work status and life status of uncontrolled non-valvular atrial fibrillation (NVAF) patients is presented.</description>
          <population>All patients with non-valvular atrial fibrillation (NVAF), who received conventional vitamin K antagonist (VKA) treatment at least 6 months and up to 2 years with uncontrolled anticoagulation status were included.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Work status - Employed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Work status - Housewife</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Work status - Retired</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Work status - Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Life status - Single</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Life status - Married</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Life status - Widowed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Life status - Divorced</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age &lt; 65</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age 65 - 75</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age ≥ 75</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Height of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients</title>
        <description>Height of uncontrolled non-valvular atrial fibrillation (NVAF) patients is presented.</description>
        <time_frame>The study consisted of a single visit between April 2017 and January 2018</time_frame>
        <population>All patients with non-valvular atrial fibrillation (NVAF), who received conventional vitamin K antagonist (VKA) treatment at least 6 months and up to 2 years with uncontrolled anticoagulation status were included. The number of patients included in the analysis of this variable has been specified.</population>
        <group_list>
          <group group_id="O1">
            <title>Uncontrolled Group</title>
            <description>Patients with non-valvular atrial fibrillation (NVAF) receiving conventional vitamin K antagonist (VKA) treatment for at least 6 months and up to 2 years with uncontrolled anticoagulation status were included in this group.</description>
          </group>
        </group_list>
        <measure>
          <title>Height of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients</title>
          <description>Height of uncontrolled non-valvular atrial fibrillation (NVAF) patients is presented.</description>
          <population>All patients with non-valvular atrial fibrillation (NVAF), who received conventional vitamin K antagonist (VKA) treatment at least 6 months and up to 2 years with uncontrolled anticoagulation status were included. The number of patients included in the analysis of this variable has been specified.</population>
          <units>Centimeter (cm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163.1" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weight of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients</title>
        <description>Weight of uncontrolled non-valvular atrial fibrillation (NVAF) patients is presented.</description>
        <time_frame>The study consisted of a single visit between April 2017 and January 2018</time_frame>
        <population>All patients with non-valvular atrial fibrillation (NVAF), who received conventional vitamin K antagonist (VKA) treatment at least 6 months and up to 2 years with uncontrolled anticoagulation status were included. The number of patients included in the analysis of this variable has been specified.</population>
        <group_list>
          <group group_id="O1">
            <title>Uncontrolled Group</title>
            <description>Patients with non-valvular atrial fibrillation (NVAF) receiving conventional vitamin K antagonist (VKA) treatment for at least 6 months and up to 2 years with uncontrolled anticoagulation status were included in this group.</description>
          </group>
        </group_list>
        <measure>
          <title>Weight of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients</title>
          <description>Weight of uncontrolled non-valvular atrial fibrillation (NVAF) patients is presented.</description>
          <population>All patients with non-valvular atrial fibrillation (NVAF), who received conventional vitamin K antagonist (VKA) treatment at least 6 months and up to 2 years with uncontrolled anticoagulation status were included. The number of patients included in the analysis of this variable has been specified.</population>
          <units>Kilogram (kg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.5" spread="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Mass Index (BMI) of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients</title>
        <description>BMI of uncontrolled non-valvular atrial fibrillation (NVAF) patients is presented.</description>
        <time_frame>The study consisted of a single visit between April 2017 and January 2018</time_frame>
        <population>All patients with non-valvular atrial fibrillation (NVAF), who received conventional vitamin K antagonist (VKA) treatment at least 6 months and up to 2 years with uncontrolled anticoagulation status were included. The number of patients included in the analysis of this variable has been specified.</population>
        <group_list>
          <group group_id="O1">
            <title>Uncontrolled Group</title>
            <description>Patients with non-valvular atrial fibrillation (NVAF) receiving conventional vitamin K antagonist (VKA) treatment for at least 6 months and up to 2 years with uncontrolled anticoagulation status were included in this group.</description>
          </group>
        </group_list>
        <measure>
          <title>Body Mass Index (BMI) of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients</title>
          <description>BMI of uncontrolled non-valvular atrial fibrillation (NVAF) patients is presented.</description>
          <population>All patients with non-valvular atrial fibrillation (NVAF), who received conventional vitamin K antagonist (VKA) treatment at least 6 months and up to 2 years with uncontrolled anticoagulation status were included. The number of patients included in the analysis of this variable has been specified.</population>
          <units>Kilogram/meter^2 (kg/m^2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.7" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kidney Function (Creatinine Clearance) of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients</title>
        <description>Kidney function of uncontrolled non-valvular atrial fibrillation (NVAF) patients measured by creatinine clearance is presented.</description>
        <time_frame>The study consisted of a single visit between April 2017 and January 2018</time_frame>
        <population>All patients with non-valvular atrial fibrillation (NVAF), who received conventional vitamin K antagonist (VKA) treatment at least 6 months and up to 2 years with uncontrolled anticoagulation status were included. The number of patients included in the analysis of this variable has been specified.</population>
        <group_list>
          <group group_id="O1">
            <title>Uncontrolled Group</title>
            <description>Patients with non-valvular atrial fibrillation (NVAF) receiving conventional vitamin K antagonist (VKA) treatment for at least 6 months and up to 2 years with uncontrolled anticoagulation status were included in this group.</description>
          </group>
        </group_list>
        <measure>
          <title>Kidney Function (Creatinine Clearance) of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients</title>
          <description>Kidney function of uncontrolled non-valvular atrial fibrillation (NVAF) patients measured by creatinine clearance is presented.</description>
          <population>All patients with non-valvular atrial fibrillation (NVAF), who received conventional vitamin K antagonist (VKA) treatment at least 6 months and up to 2 years with uncontrolled anticoagulation status were included. The number of patients included in the analysis of this variable has been specified.</population>
          <units>Millilitre/minute (ml/min)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.2" spread="26.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>History of Non-valvular Atrial Fibrillation (NVAF) - Time Since Diagnosis</title>
        <description>Analysis of data regarding the specific NVAF profile of uncontrolled patients indicated that the average (± SD) time since diagnosis (calculated as the time from the date of diagnosis to the date of the baseline visit).</description>
        <time_frame>The study consisted of a single visit between April 2017 and January 2018</time_frame>
        <population>All patients with non-valvular atrial fibrillation (NVAF), who received conventional vitamin K antagonist (VKA) treatment at least 6 months and up to 2 years with uncontrolled anticoagulation status were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Uncontrolled Group</title>
            <description>Patients with non-valvular atrial fibrillation (NVAF) receiving conventional vitamin K antagonist (VKA) treatment for at least 6 months and up to 2 years with uncontrolled anticoagulation status were included in this group.</description>
          </group>
        </group_list>
        <measure>
          <title>History of Non-valvular Atrial Fibrillation (NVAF) - Time Since Diagnosis</title>
          <description>Analysis of data regarding the specific NVAF profile of uncontrolled patients indicated that the average (± SD) time since diagnosis (calculated as the time from the date of diagnosis to the date of the baseline visit).</description>
          <population>All patients with non-valvular atrial fibrillation (NVAF), who received conventional vitamin K antagonist (VKA) treatment at least 6 months and up to 2 years with uncontrolled anticoagulation status were included.</population>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>History of Non-valvular Atrial Fibrillation (NVAF) - Age at Diagnosis</title>
        <description>Age at diagnosis of uncontrolled non-valvular atrial fibrillation (NVAF) patients is presented.</description>
        <time_frame>The study consisted of a single visit between April 2017 and January 2018</time_frame>
        <population>All patients with non-valvular atrial fibrillation (NVAF), who received conventional vitamin K antagonist (VKA) treatment at least 6 months and up to 2 years with uncontrolled anticoagulation status were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Uncontrolled Group</title>
            <description>Patients with non-valvular atrial fibrillation (NVAF) receiving conventional vitamin K antagonist (VKA) treatment for at least 6 months and up to 2 years with uncontrolled anticoagulation status were included in this group.</description>
          </group>
        </group_list>
        <measure>
          <title>History of Non-valvular Atrial Fibrillation (NVAF) - Age at Diagnosis</title>
          <description>Age at diagnosis of uncontrolled non-valvular atrial fibrillation (NVAF) patients is presented.</description>
          <population>All patients with non-valvular atrial fibrillation (NVAF), who received conventional vitamin K antagonist (VKA) treatment at least 6 months and up to 2 years with uncontrolled anticoagulation status were included.</population>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.3" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricular Ejection Fraction (LVEF) of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients</title>
        <description>Left ventricular ejection fraction (LVEF) of uncontrolled non-valvular atrial fibrillation (NVAF) patients is presented.</description>
        <time_frame>The study consisted of a single visit between April 2017 and January 2018</time_frame>
        <population>All patients with non-valvular atrial fibrillation (NVAF), who received conventional vitamin K antagonist (VKA) treatment at least 6 months and up to 2 years with uncontrolled anticoagulation status were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Uncontrolled Group</title>
            <description>Patients with non-valvular atrial fibrillation (NVAF) receiving conventional vitamin K antagonist (VKA) treatment for at least 6 months and up to 2 years with uncontrolled anticoagulation status were included in this group.</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Ejection Fraction (LVEF) of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients</title>
          <description>Left ventricular ejection fraction (LVEF) of uncontrolled non-valvular atrial fibrillation (NVAF) patients is presented.</description>
          <population>All patients with non-valvular atrial fibrillation (NVAF), who received conventional vitamin K antagonist (VKA) treatment at least 6 months and up to 2 years with uncontrolled anticoagulation status were included.</population>
          <units>Percentage (%)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.1" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Left Ventricular Ejection Fraction (LVEF) Depression of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients</title>
        <description>Percentage of patients with left ventricular ejection fraction (LVEF) depression (% of LVEF depression) of uncontrolled non-valvular atrial fibrillation (NVAF) patients is presented qualitatively.</description>
        <time_frame>The study consisted of a single visit between April 2017 and January 2018</time_frame>
        <population>All patients with non-valvular atrial fibrillation (NVAF), who received conventional vitamin K antagonist (VKA) treatment at least 6 months and up to 2 years with uncontrolled anticoagulation status were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Uncontrolled Group</title>
            <description>Patients with non-valvular atrial fibrillation (NVAF) receiving conventional vitamin K antagonist (VKA) treatment for at least 6 months and up to 2 years with uncontrolled anticoagulation status were included in this group.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Left Ventricular Ejection Fraction (LVEF) Depression of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients</title>
          <description>Percentage of patients with left ventricular ejection fraction (LVEF) depression (% of LVEF depression) of uncontrolled non-valvular atrial fibrillation (NVAF) patients is presented qualitatively.</description>
          <population>All patients with non-valvular atrial fibrillation (NVAF), who received conventional vitamin K antagonist (VKA) treatment at least 6 months and up to 2 years with uncontrolled anticoagulation status were included.</population>
          <units>Percentage of patients (%)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Normal (≥ 50%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slightly depressed (41-49%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately depressed (31-40%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severely depressed (≤ 30%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CHA2DS2-VASc Score of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients</title>
        <description>CHA2DS2-VASc stroke risk score is calculated based on the following conditions: Congestive heart failure, Hypertension, Age (≥ 75), Diabetes Mellitus, Stroke/ Transient Ischaemic Attack (TIA), Vascular disease, Age 65-74, Sex category. CHA2DS2-VASc stroke risk score may range from 0 to 9 with 0 being the best outcome.</description>
        <time_frame>The study consisted of a single visit between April 2017 and January 2018</time_frame>
        <population>All patients with non-valvular atrial fibrillation (NVAF), who received conventional vitamin K antagonist (VKA) treatment at least 6 months and up to 2 years with uncontrolled anticoagulation status were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Uncontrolled Group</title>
            <description>Patients with non-valvular atrial fibrillation (NVAF) receiving conventional vitamin K antagonist (VKA) treatment for at least 6 months and up to 2 years with uncontrolled anticoagulation status were included in this group.</description>
          </group>
        </group_list>
        <measure>
          <title>CHA2DS2-VASc Score of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients</title>
          <description>CHA2DS2-VASc stroke risk score is calculated based on the following conditions: Congestive heart failure, Hypertension, Age (≥ 75), Diabetes Mellitus, Stroke/ Transient Ischaemic Attack (TIA), Vascular disease, Age 65-74, Sex category. CHA2DS2-VASc stroke risk score may range from 0 to 9 with 0 being the best outcome.</description>
          <population>All patients with non-valvular atrial fibrillation (NVAF), who received conventional vitamin K antagonist (VKA) treatment at least 6 months and up to 2 years with uncontrolled anticoagulation status were included.</population>
          <units>Unit on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HAS-BLED Score of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients</title>
        <description>HAS-BLED bleeding risk score is calculated based on the following conditions: Hypertension, Abnormal renal and liver function, Stroke, Bleeding history or predisposition, Labile International Normalized Ratio (INR), Elderly (&gt;65 years), Drugs and Alcohol. HAS-BLED bleeding risk score may range from 0 to 9 with 0 being the best outcome.</description>
        <time_frame>The study consisted of a single visit between April 2017 and January 2018</time_frame>
        <population>All patients with non-valvular atrial fibrillation (NVAF), who received conventional vitamin K antagonist (VKA) treatment at least 6 months and up to 2 years with uncontrolled anticoagulation status were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Uncontrolled Group</title>
            <description>Patients with non-valvular atrial fibrillation (NVAF) receiving conventional vitamin K antagonist (VKA) treatment for at least 6 months and up to 2 years with uncontrolled anticoagulation status were included in this group.</description>
          </group>
        </group_list>
        <measure>
          <title>HAS-BLED Score of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients</title>
          <description>HAS-BLED bleeding risk score is calculated based on the following conditions: Hypertension, Abnormal renal and liver function, Stroke, Bleeding history or predisposition, Labile International Normalized Ratio (INR), Elderly (&gt;65 years), Drugs and Alcohol. HAS-BLED bleeding risk score may range from 0 to 9 with 0 being the best outcome.</description>
          <population>All patients with non-valvular atrial fibrillation (NVAF), who received conventional vitamin K antagonist (VKA) treatment at least 6 months and up to 2 years with uncontrolled anticoagulation status were included.</population>
          <units>Unit on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients With History of Thromboembolic Events by Categories</title>
        <description>Percentage of uncontrolled non-valvular atrial fibrillation (NVAF) patients with history of thromboembolic events by categories are presented.</description>
        <time_frame>The study consisted of a single visit between April 2017 and January 2018</time_frame>
        <population>All patients with non-valvular atrial fibrillation (NVAF), who received conventional vitamin K antagonist (VKA) treatment at least 6 months and up to 2 years with uncontrolled anticoagulation status were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Uncontrolled Group</title>
            <description>Patients with non-valvular atrial fibrillation (NVAF) receiving conventional vitamin K antagonist (VKA) treatment for at least 6 months and up to 2 years with uncontrolled anticoagulation status were included in this group.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients With History of Thromboembolic Events by Categories</title>
          <description>Percentage of uncontrolled non-valvular atrial fibrillation (NVAF) patients with history of thromboembolic events by categories are presented.</description>
          <population>All patients with non-valvular atrial fibrillation (NVAF), who received conventional vitamin K antagonist (VKA) treatment at least 6 months and up to 2 years with uncontrolled anticoagulation status were included.</population>
          <units>Percentage of patients (%)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-ST segment elevation myocardial infarction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cerebral infarction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulmonary embolism</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable angina pectoris</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ST-segment elevation myocardial infarction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unstable angina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deep vein thrombosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic embolism</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients With History of Haemorrhagic Events by Categories</title>
        <description>Percentage of uncontrolled non-valvular atrial fibrillation (NVAF) patients with history of haemorrhagic events by categories are presented.</description>
        <time_frame>The study consisted of a single visit between April 2017 and January 2018</time_frame>
        <population>All patients with non-valvular atrial fibrillation (NVAF), who received conventional vitamin K antagonist (VKA) treatment at least 6 months and up to 2 years with uncontrolled anticoagulation status were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Uncontrolled Group</title>
            <description>Patients with non-valvular atrial fibrillation (NVAF) receiving conventional vitamin K antagonist (VKA) treatment for at least 6 months and up to 2 years with uncontrolled anticoagulation status were included in this group.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients With History of Haemorrhagic Events by Categories</title>
          <description>Percentage of uncontrolled non-valvular atrial fibrillation (NVAF) patients with history of haemorrhagic events by categories are presented.</description>
          <population>All patients with non-valvular atrial fibrillation (NVAF), who received conventional vitamin K antagonist (VKA) treatment at least 6 months and up to 2 years with uncontrolled anticoagulation status were included.</population>
          <units>Percentage of patients (%)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Gastrointestinal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genitourinary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulmonary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Articular-muscular</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intracranial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Conjunctival</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Visits to the Physician of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients</title>
        <description>Number of visits to the internal medicine specialist per year of uncontrolled non-valvular atrial fibrillation (NVAF) patients is presented.</description>
        <time_frame>The study consisted of a single visit between April 2017 and January 2018</time_frame>
        <population>All patients with non-valvular atrial fibrillation (NVAF), who received conventional vitamin K antagonist (VKA) treatment at least 6 months and up to 2 years with uncontrolled anticoagulation status were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Uncontrolled Group</title>
            <description>Patients with non-valvular atrial fibrillation (NVAF) receiving conventional vitamin K antagonist (VKA) treatment for at least 6 months and up to 2 years with uncontrolled anticoagulation status were included in this group.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Visits to the Physician of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients</title>
          <description>Number of visits to the internal medicine specialist per year of uncontrolled non-valvular atrial fibrillation (NVAF) patients is presented.</description>
          <population>All patients with non-valvular atrial fibrillation (NVAF), who received conventional vitamin K antagonist (VKA) treatment at least 6 months and up to 2 years with uncontrolled anticoagulation status were included.</population>
          <units>Visits per year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Therapeutic Time in Range (TTR%) of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients</title>
        <description>Therapeutic time in range (TTR%) of uncontrolled non-valvular atrial fibrillation (NVAF) patients determined by the Rosendaal method (poor control &lt; 65%) or by the direct method (poor control &lt; 60%).</description>
        <time_frame>The study consisted of a single visit between April 2017 and January 2018</time_frame>
        <population>All patients with non-valvular atrial fibrillation (NVAF), who received conventional vitamin K antagonist (VKA) treatment at least 6 months and up to 2 years with uncontrolled anticoagulation status were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Uncontrolled Group</title>
            <description>Patients with non-valvular atrial fibrillation (NVAF) receiving conventional vitamin K antagonist (VKA) treatment for at least 6 months and up to 2 years with uncontrolled anticoagulation status were included in this group.</description>
          </group>
        </group_list>
        <measure>
          <title>Therapeutic Time in Range (TTR%) of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients</title>
          <description>Therapeutic time in range (TTR%) of uncontrolled non-valvular atrial fibrillation (NVAF) patients determined by the Rosendaal method (poor control &lt; 65%) or by the direct method (poor control &lt; 60%).</description>
          <population>All patients with non-valvular atrial fibrillation (NVAF), who received conventional vitamin K antagonist (VKA) treatment at least 6 months and up to 2 years with uncontrolled anticoagulation status were included.</population>
          <units>Percentage (%)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Rosendaal method (poor control &lt; 65%)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.1" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>The direct method (poor control &lt; 60%)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.0" spread="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Since Treatment Initiation of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients</title>
        <description>Time since treatment initiation of uncontrolled non-valvular atrial fibrillation (NVAF) patients was calculated as the time from the start date of treatment to the date of the baseline visit.</description>
        <time_frame>The study consisted of a single visit between April 2017 and January 2018</time_frame>
        <population>All patients with non-valvular atrial fibrillation (NVAF), who received conventional vitamin K antagonist (VKA) treatment at least 6 months and up to 2 years with uncontrolled anticoagulation status were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Uncontrolled Group</title>
            <description>Patients with non-valvular atrial fibrillation (NVAF) receiving conventional vitamin K antagonist (VKA) treatment for at least 6 months and up to 2 years with uncontrolled anticoagulation status were included in this group.</description>
          </group>
        </group_list>
        <measure>
          <title>Time Since Treatment Initiation of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients</title>
          <description>Time since treatment initiation of uncontrolled non-valvular atrial fibrillation (NVAF) patients was calculated as the time from the start date of treatment to the date of the baseline visit.</description>
          <population>All patients with non-valvular atrial fibrillation (NVAF), who received conventional vitamin K antagonist (VKA) treatment at least 6 months and up to 2 years with uncontrolled anticoagulation status were included.</population>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients Received Type of VKA Treatment</title>
        <description>Percentage of uncontrolled non-valvular atrial fibrillation (NVAF) patients received type VKA treatment is presented.</description>
        <time_frame>The study consisted of a single visit between April 2017 and January 2018</time_frame>
        <population>All patients with non-valvular atrial fibrillation (NVAF), who received conventional vitamin K antagonist (VKA) treatment at least 6 months and up to 2 years with uncontrolled anticoagulation status were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Uncontrolled Group</title>
            <description>Patients with non-valvular atrial fibrillation (NVAF) receiving conventional vitamin K antagonist (VKA) treatment for at least 6 months and up to 2 years with uncontrolled anticoagulation status were included in this group.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients Received Type of VKA Treatment</title>
          <description>Percentage of uncontrolled non-valvular atrial fibrillation (NVAF) patients received type VKA treatment is presented.</description>
          <population>All patients with non-valvular atrial fibrillation (NVAF), who received conventional vitamin K antagonist (VKA) treatment at least 6 months and up to 2 years with uncontrolled anticoagulation status were included.</population>
          <units>Percentage of patients (%)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Acenocoumarol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.7" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Warfarin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients With Concomitant Diseases</title>
        <description>The percentage of uncontrolled non-valvular atrial fibrillation (NVAF) patients with at least one other concomitant diseases recorded in the medical history.</description>
        <time_frame>The study consisted of a single visit between April 2017 and January 2018</time_frame>
        <population>All patients with non-valvular atrial fibrillation (NVAF), who received conventional vitamin K antagonist (VKA) treatment at least 6 months and up to 2 years with uncontrolled anticoagulation status were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Uncontrolled Group</title>
            <description>Patients with non-valvular atrial fibrillation (NVAF) receiving conventional vitamin K antagonist (VKA) treatment for at least 6 months and up to 2 years with uncontrolled anticoagulation status were included in this group.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients With Concomitant Diseases</title>
          <description>The percentage of uncontrolled non-valvular atrial fibrillation (NVAF) patients with at least one other concomitant diseases recorded in the medical history.</description>
          <population>All patients with non-valvular atrial fibrillation (NVAF), who received conventional vitamin K antagonist (VKA) treatment at least 6 months and up to 2 years with uncontrolled anticoagulation status were included.</population>
          <units>Percentage of patients (%)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hypertension</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="169"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Congestive heart failure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="169"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diabetes mellitus</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="169"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal failure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="169"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anaemia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="169"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arterial vascular disease</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="169"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Previous stroke/transient ischaemic attack (TIA)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="169"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Venous thromboembolism</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="169"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liver failure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="169"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="169"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients With Active Concomitant Diseases on Visit Day</title>
        <description>The percentage of uncontrolled non-valvular atrial fibrillation (NVAF) patients with active concomitant diseases on visit day. The percentage was calculated on total patients who presented each of the diseases.</description>
        <time_frame>The study consisted of a single visit between April 2017 and January 2018</time_frame>
        <population>All patients with non-valvular atrial fibrillation (NVAF), who received conventional vitamin K antagonist (VKA) treatment at least 6 months and up to 2 years with uncontrolled anticoagulation status were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Uncontrolled Group</title>
            <description>Patients with non-valvular atrial fibrillation (NVAF) receiving conventional vitamin K antagonist (VKA) treatment for at least 6 months and up to 2 years with uncontrolled anticoagulation status were included in this group.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients With Active Concomitant Diseases on Visit Day</title>
          <description>The percentage of uncontrolled non-valvular atrial fibrillation (NVAF) patients with active concomitant diseases on visit day. The percentage was calculated on total patients who presented each of the diseases.</description>
          <population>All patients with non-valvular atrial fibrillation (NVAF), who received conventional vitamin K antagonist (VKA) treatment at least 6 months and up to 2 years with uncontrolled anticoagulation status were included.</population>
          <units>Percentage of patients (%)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Congestive heart failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diabetes mellitus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kidney failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anaemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arterial vascular disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Previous stroke/TIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liver failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Venous thromboembolism</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients With Concomitant Treatment</title>
        <description>The percentage of uncontrolled non-valvular atrial fibrillation (NVAF) patients with concomitant treatment is presented.</description>
        <time_frame>The study consisted of a single visit between April 2017 and January 2018</time_frame>
        <population>All patients with non-valvular atrial fibrillation (NVAF), who received conventional vitamin K antagonist (VKA) treatment at least 6 months and up to 2 years with uncontrolled anticoagulation status were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Uncontrolled Group</title>
            <description>Patients with non-valvular atrial fibrillation (NVAF) receiving conventional vitamin K antagonist (VKA) treatment for at least 6 months and up to 2 years with uncontrolled anticoagulation status were included in this group.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients With Concomitant Treatment</title>
          <description>The percentage of uncontrolled non-valvular atrial fibrillation (NVAF) patients with concomitant treatment is presented.</description>
          <population>All patients with non-valvular atrial fibrillation (NVAF), who received conventional vitamin K antagonist (VKA) treatment at least 6 months and up to 2 years with uncontrolled anticoagulation status were included.</population>
          <units>Percentage of patients (%)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events collected during the study period between April 2017 and January 2018; up to 41 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Uncontrolled Group</title>
          <description>Patients with non-valvular atrial fibrillation (NVAF) receiving conventional vitamin K antagonist (VKA) treatment for at least 6 months and up to 2 years with uncontrolled anticoagulation status were included in this group.</description>
        </group>
        <group group_id="E2">
          <title>VKA Controlled Group</title>
          <description>Patients with non-valvular atrial fibrillation (NVAF), who received conventional vitamin K antagonist (VKA) treatment for at least 6 months and up to 2 years with controlled anticoagulation status, were included in this group.</description>
        </group>
        <group group_id="E3">
          <title>DOAC Controlled Group</title>
          <description>Patients with non-valvular atrial fibrillation (NVAF), who received direct oral anticoagulant (DOAC) treatment for at least 6 months and up to 2 years with controlled anticoagulation status, were included in this group.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI’s intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim, Call Centre</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

